

USSN 10/813,870

CT-2773 NP

**Remarks**

**Restriction requirement.** The examiner required an inter-claim election between group I (drawn to chemical compounds and compositions) and group II (drawn to methods of treatment). In response, the applicants provisionally elect group I with traverse.

Because the method of treatment claims relate directly to the scope of the compound claims and will be rejoined with subsequently allowed compound claims under MPEP 821.04 (as noted by the examiner), the applicants traverse the requirement as creating more of a burden for the examiner than examining the claims together.

In response to the requirement to elect a species, the applicants provisionally elect (3R)-N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[(3S)-3-[cyclohexyl(5-isoxazolylcarbonyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (example 18). Claims 1-5 and 8-11 read on this compound.


The examiner made no requirement for an intra-claim restriction.

The applicants believe they have complied with all of the examiners requirements and respectfully request favorably reconsideration of the restriction requirement.

Sincerely,

Date: 6/8/2005

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000

  
James Epperson  
Agent for Applicants  
Reg. No. 52,867  
Phone: (203) 677-6974